<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161388">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01829295</url>
  </required_header>
  <id_info>
    <org_study_id>EY021125-01</org_study_id>
    <nct_id>NCT01829295</nct_id>
  </id_info>
  <brief_title>Methotrexate and Mycophenolate Mofetil for UVEITIS</brief_title>
  <acronym>FAST</acronym>
  <official_title>First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aravind Eye Hospitals, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociacion Para Evitar La Ceguera en Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Victoria Eye and Ear Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the
      investigators propose to establish which immunosuppressive therapy, methotrexate or
      mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for
      the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative
      effectiveness trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treatment Success</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Controlled ocular inflammation (≤ 0.5+ anterior chamber cells, ≤ 0.5+ vitreous haze, no active retinal/choroidal lesions in both eyes) with ≤ 7.5 mg/day of oral prednisone and ≤ 2 drops/day of topical 1% prednisolone acetate.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral mycophenolate mofetil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunosuppressive therapy (oral methotrexate,  oral mycophenolate mofetil)</intervention_name>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Mycophenolate Mofetil</arm_group_label>
    <other_name>antimetabolite treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All the following criteria must be met at enrollment:

        Historical non-infectious intermediate, anterior and intermediate, posterior or panuveitis
        in at least one eye

        Active inflammation within the last 90 days, defined by the presence of any of the
        following (in at least one eye) according to SUN criteria:

          -  2+ anterior chamber cells

          -  2+ vitreous haze active retinal or choroidal lesions

        At least one of the following criteria must be met before or at enrollment:

          1. Active inflammation after 4 weeks of high-dose (1mg/kg prednisone equivalent)
             corticosteroid treatment or 4 weeks following a regional corticosteroid injection

          2. Treatment with oral corticosteroids resulting in a reduction of inflammation,
             followed by an increase in inflammation (of at least 1 grade in anterior chamber
             cells or vitreous haze or a change of non-active to active lesions) when
             corticosteroid is tapered, in the 2 weeks prior to enrollment

          3. Known chronic condition necessitating corticosteroid-sparing immunosuppressive
             treatment

        At least 1+ anterior chamber cells and/or 1+ vitreous haze and/or active retinal/choroidal
        lesions (bullous serous retinal detachment qualifies) in at least one eye at enrollment.

        Willingness to start corticosteroid treatment at 1mg/kg or 60mg a day of prednisone,
        whichever is less

        Willingness to abstain from alcohol (2 drinks per month is okay)

        Willingness to use an acceptable method of contraception during the study period (i.e.
        pharmacologics, devices, barrier methods) or abstinence.

        Exclusion Criteria:

        Any infectious cause of uveitis

        Media opacity (such as cataract and/or corneal scar) and/or extensive posterior synechiae
        such that examination of the posterior segment is not possible in both eyes

        Chronic hypotony (IOP &lt; 5 mm Hg for &gt; 3 months) in both eyes

        Prior use of any immunosuppressive drug other than prednisone

        Periocular or intravitreal corticosteroid injection in the past 4 weeks

        Fluocinolone acetonide implant in either eye in &lt; 3 years

        Intraocular surgery in &lt; 30 days, or planning on getting surgery within the next 6 months

        Best spectacle-corrected visual acuity (BSCVA) of hand motions or worse in better eye

        &lt; 16 years of age at enrollment

        Planning to conceive during the study period, pregnant or breast-feeding (blood or urine
        pregnancy test for all females, excluding those who are post-menopausal is mandatory)*

        Cancer (If a patient has a history of non-melanoma skin cancer they can still be
        considered for inclusion in this study, provided it is not  currently active.

        Systemic autoimmune disease anticipated to dictate treatment course

        Abnormal CBC (≤ 2,500 white blood cells and/or ≤ 75,000 platelets and/or ≤9 hemoglobin)
        within 4 weeks prior to enrollment*

        Abnormal alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 2 times
        the upper limit of normal for the lab and/or creatinine ≥ 1.5 within 4 weeks prior to
        enrollment*

        Evidence of active tuberculosis, HIV infection, syphilis, or hepatitis B or C (patients
        must have a tuberculin skin test, or interferon-gamma release assay, a chest radiograph,
        RPR/VDRL, FTA-ABS, or other treponemal tests, Hepatitis B surface antigen, Hepatitis C
        antibody tests, and HIV test within 90 days prior to enrollment)**

        *Testing required within 14 days prior to enrollment; **Testing required within 90 days
        prior to enrollment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nisha Acharya, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nisha Acharya, MD</last_name>
    <phone>4154768183</phone>
    <email>nisha.acharya@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Weinrib, MPH</last_name>
    <phone>4154676687</phone>
    <email>rachel.weinrib@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Proctor Foundation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Weinrib, MPH</last_name>
      <phone>415-476-6687</phone>
      <email>rachel.weinrib@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sally Tsang, MA</last_name>
      <phone>4154761442</phone>
      <email>sally.tsang@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nisha Acharya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debra Goldstein, MD</last_name>
      <email>debrgold@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Castro-Malek</last_name>
      <email>annaliza.castro@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Debra Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University - Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Suhler, MD</last_name>
      <email>eric.suhler@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Tracy Giles</last_name>
      <phone>503-494-0482</phone>
      <email>gilest@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Suhler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victorian Eye and Ear Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyndell Lim, MD</last_name>
      <email>limllp@unimelb.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Julie Morrison</last_name>
      <email>jl.morrison@unimelb.edu.au</email>
    </contact_backup>
    <investigator>
      <last_name>Lyndell Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anuradha, MD</last_name>
      <email>kanakath@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Princy</last_name>
      <email>princycrc@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anu Kanakath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aravind Eye Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>S.R. Rathinam, MD PhD</last_name>
      <email>rathinam@aravind.org</email>
    </contact>
    <contact_backup>
      <last_name>Gobinath Kanagaraj</last_name>
      <email>k.gobibpharm@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>S.R. Rathinam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asociacion Para Evita La Ceguera en Mexico</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico, D.F.</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lourdes Arellanes, MD</last_name>
      <email>lourdes.arellanes@apec.com.mx</email>
    </contact>
    <contact_backup>
      <last_name>Yoko Burgoa</last_name>
      <email>yokoburgoa@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lourdes Arellanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>India</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Chorioretinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antimetabolites</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
